Prior to the acquisition of ICOS on January 29, 2007, Cialis sales in Lilly territories were reported in Lilly's revenue, while Lilly's 50 percent share of the joint-venture territory sales, net of expenses, was reported in Lilly's other income. After the acquisition of ICOS, all Cialis sales are reported in Lilly's revenue.
Evista sales were $285.8 million in the fourth quarter, a 6 percent increase compared with the fourth quarter of 2006. U.S. sales of Evista increased 6 percent, to $187.7 million, driven by higher prices. Sales outside the U.S. increased 5 percent, to $98.1 million, driven primarily by favorable exchange rates and higher prices, partially offset by lower demand.
For the full year of 2007, worldwide Evista sales increased 4 percent, to $1.091 billion. U.S. Evista sales for 2007 were $706.1 million, a 6 percent increase driven by higher prices. Evista sales outside the U.S. were $384.6 million, a 1 percent increase, driven by favorable exchange rates, offset in part by declining prices and lower demand.
Worldwide Humulin sales increased 6 percent in the fourth quarter, to $273.4 million. U.S. sales declined 2 percent to $101.5 million due to lower demand, partially offset by higher prices. Sales outside the U.S. increased 12 percent to $171.9 million, driven primarily by the favorable impact of foreign exchange rates.
For the full year of 2007, worldwide Humulin sales increased 6 percent,
to $985.2 million. U.S. Humulin sales for 2007 were $365.2 million, a 1
percent decrease driven by lower demand, offset in part by higher prices.
Humulin sales outside th
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved